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Neuroendocrine tumours of the gastrointestinal tract are rare
diseases and with the presence of metastases, patients may suffer
from disabling symptoms of hormone overproduction. Potentially
curative surgery can be performed in patients with localized
disease, and sometimes in patients with liver metastases. However,
long-term follow-up of the latter patients mostly shows late
tumour recurrences (Norton, 1994). Debulking (cytoreductive)
surgery can be considered when most of the tumour burden can be
excised safely to minimize hormonal symptoms and to facilitate
medical therapy (McEntee et al, 1990; Carty et al, 1992; Que et al,
1995). An important question is whether the aggressive treatment
of metastatic disease prolongs survival. No randomized studies are
available today. Such studies are complicated by the lack of strict
surgical treatment protocols running over long periods, the rela-
tively low number of patients and the absence of a TNM (tumour,
node, metastases) classification of these tumour types. Many clin-
ical studies, in which debulking surgery and resection rates are
discussed, are composed of patients with carcinoids and those with
endocrine pancreatic tumours (EPT). However, these two disease
entities may include tumours with markedly different biology.
In our consecutive series of patients with advanced midgut
carcinoids (all with locoregional and hepatic metastases) the esti-
mated overall 5-year survival was 69% after active interventional
treatment. The 5-year survival of carcinoid patients with bilobar
liver metastases was 63% (cf. Wängberg et al, 1996). These
figures are superior to the ones obtained after more conservative
treatment. In a consecutive series of 42 patients with metastatic
EPT from National Institutes of Health, the 5-year survival of
those 17 patients resected for cure was 79% versus 28% in the
non-resected group (Carty et al, 1992). Similar results were
recently reported from the Mayo Clinic in 74 patients with hepatic
metastases from either EPT or carcinoid tumours. The 4-year
survival was 85% for one-third of the patients selected for resec-
tion versus 65% for the two-thirds non-resected (Que et al, 1995).
In a recent French series of 34 patients with neuroendocrine
tumours (carcinoids and EPT) and hepatic metastases, the liver
resection rate was as high as 50%. Twelve of these 17 patients
were operated upon with curative intent (Dousset et al, 1996).
The aim of this retrospective study was to compare survival in
our consecutive series of patients with malignant EPT with that
of patients with advanced midgut carcinoids when subjected to
similar treatment principles. Furthermore, EPT were staged
according to the TNM classification of pancreatic carcinoma. By
doing so, stage IV tumours should be compared with advanced
carcinoid tumours with liver metastases.
MATERIALS AND METHODS
Patients and treatment
The 64 consecutive patients with advanced midgut carcinoids
were treated during 1987–1997 (cf. Wängberg et al, 1996). All
patients underwent primary surgery, removal of the primary
tumour and regional lymph node metastases, and excision of
retroperitoneal tumours when present. Fourteen patients with
unilobar hepatic lesions had a second operation (liver resection)
with curative intent. Forty patients with multilobar liver metas-
tases underwent ischaemic tumour reduction by hepatic arterial
embolization, followed by octreotide treatment. Ten patients
underwent only primary surgery, followed by octreotide in combi-
nation with interferon since further interventional treatment was
contraindicated (high age, synchronous malignancies, thrombo-
embolic disease, cirrhosis or psychiatric disorders). At tumour
progression, additional treatment with cytotoxic drugs was given
(streptozotocin and 5-fluorouracil alternated with doxorubicin; cf.
Moertel et al, 1994).
During the same period, 25 consecutive patients with sporadic
malignant EPT (mean age 50 years, range 17–77) were treated at
our unit. All patients were surgically explored and underwent
radical surgery or surgical debulking, if more than 90% of the
intrahepatic metastases could be removed safely (cf. Foster and
Lundy, 1981). Tumour staging was done according to the 1997
TNM classification of pancreatic carcinoma (Table 1). The series
of malignant sporadic EPT included two glucagonomas (stage I
and III), three insulinomas (stage I, n = 1; stage IV, n = 2), five
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Correspondence to: V Johansongastrinomas (stage III, n = 2; stage IV, n = 3), six neuroendocrine
carcinomas (NEC), (cf. Gould et al, 1984) (all stage IV) and nine
non-functional islet cell tumours (stage I, n = 3; stage III, n = 3;
stage IV, n = 3). Five patients with sporadic EPT stage I were
classified as malignant due to histopathological criteria (n = 4), or
later appearance of metastases (n = 1).
Eleven out of the 25 EPT patients were resected for cure.
Seventeen patients had their primary tumour removed by enucle-
ation (n = 1), pancreatic resection (n = 13) or total/subtotal
pancreatectomy with regional lymph node excision (n = 3). It is
notable that all 14 patients with hepatic disease (stage IV)
presented with multilobar metastases. Hepatic debulking pro-
cedures were carried out in three patients. Seven out of 14 patients
with liver metastases were treated with hepatic arterial emboliza-
tion. All patients with liver metastases were treated medically
(octreotide combined with interferon followed by cytotoxic drugs
at tumour progression; cf. Moertel et al, 1994).
RESULTS
The survival function related to tumour disease was estimated
according to the Kaplan–Meier method. Patients with carcinoid
tumours and intentionally curative liver resection had an estimated
5-year survival of 100% versus 63% in patients treated with
hepatic artery embolization. In the group of ten patients with
solely medical treatment after primary surgery, only one patient
was alive after 5 years.
Eleven patients with resectable sporadic EPT tumours (stage I
and III) had an estimated 5-year survival of 100% versus 0% for
the 14 patients with liver metastases (stage IV) (Figure 1). Eight
patients with stage IV disease (four NEC cases) had very advanced
tumours and were not amenable to surgical treatment. The other
six patients with stage IV disease (two NEC cases) had their
primary tumours resected prior to further therapy. In the latter
group, hepatic tumour debulking could be performed in three
patients. For the EPT patients of stage IV the estimated 2-year
survival was 53%, but declined rapidly thereafter. The NEC
patients had an even worse survival with a median survival of 3
months (range 1–37 months).
DISCUSSION
Very active surgery has become accepted as the treatment of choice
for neuroendocrine tumours, many of which have a relatively slow
growth (Galland and Blumgart, 1986; McEntee et al, 1990; Norton,
1994; Dousset et al, 1996). The active treatment of patients with
advanced midgut carcinoids, including ischaemic tumour reduction
of liver metastases, has resulted in long-term palliation of hormonal
symptoms and high 5-year survival rates (Wängberg et al, 1996).
Our results from the same period of a consecutive series of patients
with advanced sporadic malignant EPT do not compare well with
recent selected series presented from large referral centres.
However, our 5-year survival figures for stage IV EPT disease
closely resemble the results after liver transplantation for metastatic
neuroendocrine tumours (bilobar disease) showing much worse
prognosis for EPT than for carcinoids (Lang et al, 1997; Le Treut et
al, 1997). In order to make reliable comparative studies it is impor-
tant to have a relevant tumour staging system, and possibly also
information on the biological behaviour of the tumour disease.
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Table 1 TNM classification of pancreatic carcinoma
T1 Limited to pancreas <2 cm
T2 Limited to pancreas >2 cm
T3 Duodenum, bile duct, peripancreatic tissues
T4 Stomach, spleen, colon, large vessels
N1 Regional lymph node metastasis
M1 Distant metastasis
Stage I T1–T2 N0 M0 n = 5
Stage II T3 N0 M0 n = 0
Stage III T1-T3 N1 M0 n = 6
Stage IV A T4 Any N M0 n = 0
Stage IV B Any T Any N M1 n = 14 (6 NEC)
n = number of patients with EPT; NEC = neuroendocrine carcinoma.
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Figure 1 Kaplan-Meier analyses of patients with neuroendocrine tumours
and liver metastases. Number of patients at risk is indicated on top of curves.
(A) Post-operative survival of patients with midgut carcinoids (MC, n = 64)
and endocrine pancreatic tumours (EPT, n = 14). (B) Survival after orthotopic
liver transplantation for metastatic neuroendocrine tumours as presented by
Le Treut et al (1997) Ann Surg 225: 355–364 (Reprinted with permission of
the publisher). Different types of carcinoid forms (n = 15) versus EPT
(n = 16)
A
BSome investigators have proposed to divide patients into stable or
progressive disease after an initial observation period prior to initia-
tion of medical therapy (Arnold et al, 1996). In the present series,
with a large proportion of patients with NEC tumours, tumour stage
IV was a very strong predictor of poor survival.
The TNM classification of pancreatic carcinoma may not
readily be applicable for EPT disease, since these tumours have a
different growth pattern, e.g. no stage II tumours were found. In
this material no EPT patient presented with unilobar liver metas-
tases, while this occurred in 14 of 64 carcinoid patients. From the
present study we conclude that high-stage sporadic EPT has a
markedly worse prognosis than midgut carcinoids of similar stage,
when the same treatment principles were followed. This means
that the two diseases should be separately analysed when treatment
is evaluated. It is important to identify patients with NEC tumours,
since they carry a particularly poor prognosis and are seldom
candidates for surgical treatment.
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